tabalumab: Clinical Trials

9 trials of tabalumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated, 3 completed. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Terminated 6, Completed 3

Follow tabalumab: new trials by email Literature Review of tabalumab trials Research Report on tabalumab

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Lupus Erythematosus, Systemic
Phase 3TerminatedEli Lilly and Company2262014-01-012018-06-15
Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Rheumatoid Arthritis
Phase 3TerminatedEli Lilly and Company82012-09-012018-04-26
On Open-Label Study in Participants With Systemic Lupus Erythematosus
LY2127399, Placebo - Systemic Lupus Erythematosus, Connective Tissue Disease
Phase 3TerminatedEli Lilly and Company15182012-01-012018-05-17
An Open Label Study for Participants With Rheumatoid Arthritis
LY2127399 - Rheumatoid Arthritis
Phase 3TerminatedEli Lilly and Company10862011-06-012018-06-11
A Rheumatoid Arthritis Study in Participants
LY2127399, Placebo - Rheumatoid Arthritis
Phase 3CompletedEli Lilly and Company10042011-01-012018-04-25
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease
Phase 3CompletedEli Lilly and Company11242011-01-012018-07-17
A Study in Participants With Rheumatoid Arthritis
LY2127399, Placebo Q4W, Placebo Q2W - Rheumatoid Arthritis
Phase 3TerminatedEli Lilly and Company4562011-01-012018-05-14
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
LY2127399, Placebo Q2W, Placebo Q4W - Rheumatoid Arthritis
Phase 3TerminatedEli Lilly and Company10412010-12-012018-05-08
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease
Phase 3CompletedEli Lilly and Company11642010-12-012018-06-12

Conditions studied

Arthritis, Rheumatoid (5)  ·  Lupus Erythematosus, Systemic (4)  ·  Autoimmune Diseases (3)  ·  Connective Tissue Diseases (3)  ·  Immune System Diseases (3)

Sponsors

Eli Lilly and Company (9)

Countries

United States (9)  ·  Argentina (6)  ·  Poland (6)  ·  Russia (6)  ·  South Korea (6)  ·  Australia (5)  ·  Colombia (5)  ·  Japan (5)  ·  Malaysia (5)  ·  Mexico (5)  ·  New Zealand (5)  ·  South Africa (5)  ·  Taiwan (5)  ·  Brazil (4)  ·  Bulgaria (4)

Results publications

PMID 27220348, PMID 27723281, PMID 29045736, PMID 31790472, PMID 35947992, PMID 38676311, PMID 25873635, PMID 26293163, PMID 26338095, PMID 26535134, PMID 33687069